Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28733983 | 0.79 | CYP19A1 (0.57) | CYP19A1DDB1CRBNCYP26A1CYP24A1 | |
| SCHEMBL28733980 | 0.79 | CYP19A1 (0.57) | CYP19A1DDB1CRBNCYP26A1CYP24A1 | |
| SCHEMBL29679745 | 0.79 | CYP19A1 (0.57) | CYP19A1DDB1CRBNCYP26A1CYP24A1 | |
| SCHEMBL8402424 | 0.72 | DDB1 (0.44) | CYP19A1DDB1CRBNCYP26A1MEN1 | |
| SCHEMBL12330473 | 0.71 | METAP1 (0.59) | CYP19A1MAOBSIGMAR1MEN1KMT2A | |
| SCHEMBL28939297 | 0.71 | CYP19A1 (0.56) | CYP19A1DDB1CRBNCYP26A1MAOB | |
| SCHEMBL29679595 | 0.71 | CYP19A1 (0.56) | CYP19A1DDB1CRBNCYP26A1MAOB | |
| SCHEMBL31112302 | 0.71 | CYP19A1 (0.70) | CYP19A1CYP26A1CYP24A1HTR1ASIGMAR1 | |
| SCHEMBL7249261 | 0.71 | CYP19A1 (0.70) | CYP19A1CYP26A1CYP24A1HTR1ASIGMAR1 | |
| SCHEMBL28939294 | 0.71 | CYP19A1 (0.56) | CYP19A1DDB1CRBNCYP26A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | CYP19A1 2314/4885DDB1 485/4885CRBN 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.